|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alper Ö, Bergmann-Leitner ES, Bennett TA,
Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth
factor receptor signaling and the invasive phenotype of ovarian
carcinoma cells. J Natl Cancer Inst. 93:1375–1384. 2001.PubMed/NCBI
|
|
5
|
van der Bilt ARM, de Vries EGE, de Jong S,
Timmer-Bosscha H, van der Zee AGJ and Reyners AKL: Turning promise
into progress for antiangiogenic agents in epithelial ovarian
cancer. Crit Rev Oncol Hematol. 84:224–242. 2012.
|
|
6
|
Masoumi Moghaddam S, Amini A, Morris D and
Pourgholami M: Significance of vascular endothelial growth factor
in growth and peritoneal dissemination of ovarian cancer. Cancer
Metastasis Rev. 31:143–162. 2012.PubMed/NCBI
|
|
7
|
Cole C, Lau S, Backen A, et al: Inhibition
of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian
cancer. Cancer Biol Ther. 10:495–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gui T and Shen K: The epidermal growth
factor receptor as a therapeutic target in epithelial ovarian
cancer. Cancer Epidemiol. 36:490–496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: new insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): Positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang BK, Lee EH and Kim HM: Inhibitory
effects of Korean folk medicine ‘Hi-Chum’ on histamine release from
mast cells in vivo and in vitro. J Ethnopharmacol.
57:73–79. 1997.
|
|
15
|
Kim H-M, Lee J-H, Won J-H, et al:
Inhibitory effect on immunoglobulin E production in vivo and
in vitro by Siegesbeckia glabrescens. Phytother Res.
15:572–576. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JY, Lim HJ and Ryu J-H: In
vitro anti-inflammatory activity of 3-O-methyl-flavones
isolated from Siegesbeckia glabrescens. Bioorg Med Chem
Lett. 18:1511–1514. 2008. View Article : Google Scholar
|
|
17
|
Li H, Kim JY, Hyeon J, Lee HJ and Ryu J-H:
In vitro antiinflammatory activity of a new Sesquiterpene
lactone isolated from Siegesbeckia glabrescens. Phytother
Res. 25:1323–1327. 2011.
|
|
18
|
Jun SY, Choi YH and Shin HM:
Siegesbeckia glabrescens induces apoptosis with different
pathways in human MCF-7 and MDA-MB-231 breast carcinoma cells.
Oncol Rep. 15:1461–1467. 2006.
|
|
19
|
Cho Y-R, Kim SH, Ko HY, Kim M-D, Choi SW
and Seo D-W: Sepiapterin inhibits cell proliferation and migration
of ovarian cancer cells via down-regulation of
p70S6K-dependent VEGFR-2 expression. Oncol Rep.
26:861–867. 2011.PubMed/NCBI
|
|
20
|
Seo D-W, Saxinger WC, Guedez L, Cantelmo
AR, Albini A and Stetler-Stevenson WG: An integrin-binding
N-terminal peptide region of TIMP-2 retains potent angio-inhibitory
and anti-tumorigenic activity in vivo. Peptides.
32:1840–1848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim SH, Cho Y-R, Kim H-J, et al:
Antagonism of VEGF-A-induced increase in vascular permeability by
an integrin α3β1-Shp-1-cAMP/PKA pathway. Blood. 120:4892–4902.
2012.PubMed/NCBI
|
|
22
|
Yoon HJ, Cho Y-R, Joo J-H and Seo D-W:
Knockdown of integrin α3β1 expression induces proliferation and
migration of non-small cell lung cancer cells. Oncol Rep.
29:662–668. 2013.
|
|
23
|
Kim SH, Cho Y-R, Kim M-D, Kim HJ, Choi SW
and Seo D-W: Inhibitory effects of sepiapterin on vascular
endothelial growth factor-A-induced proliferation and adhesion in
human umbilical vein endothelial cells. Arch Pharm Res.
34:1571–1577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho Y-R, Choi S and Seo D-W: Sepiapterin
regulates cell proliferation and migration: its association with
integrin α3β1 and p53 in human lung cancer cells. Genes Genom.
33:577–582. 2011.
|
|
25
|
Bourboulia D, Jensen-Taubman S, Rittler
MR, et al: Endogenous angiogenesis inhibitor blocks tumor growth
via direct and indirect effects on tumor microenvironment. Am J
Pathol. 179:2589–2600. 2011. View Article : Google Scholar
|
|
26
|
Hong SY, Cho JY and Seo D-W: Ginsenoside
Rp1 inhibits proliferation and migration of human lung cancer
cells. Biomol Ther. 19:411–418. 2011. View Article : Google Scholar
|
|
27
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mitra SK, Hanson DA and Schlaepfer DD:
Focal adhesion kinase: in command and control of cell motility. Nat
Rev Mol Cell Biol. 6:56–68. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Slack-Davis JK, Atkins KA, Harrer C,
Hershey ED and Conaway M: Vascular cell adhesion molecule-1 is a
regulator of ovarian cancer peritoneal metastasis. Cancer Res.
69:1469–1476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eliceiri BP: Integrin and growth factor
receptor crosstalk. Circ Res. 89:1104–1110. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hannigan GE, McDonald PC, Walsh MP and
Dedhar S: Integrin-linked kinase: Not so ‘pseudo’ after all.
Oncogene. 30:4375–4385. 2011.
|
|
33
|
Lu Y-M, Rong M-L, Shang C, et al:
Suppression of HER-2 via siRNA interference promotes apoptosis and
decreases metastatic potential of SKOV-3 human ovarian carcinoma
cells. Oncol Rep. 29:1133–1139. 2013.PubMed/NCBI
|
